RR MedSciences Pty Ltd (RRMS) is a privately held company, based in Sydney Australia. Established in 2014, the Company has focussed on the discovery and development of its core technology RM191A, since inception.
The founders of RRMS have privately funded the research and development of the Company’s novel immunomodulator. The company's novel compound and technology was developed internally at RR MedSciences. The Company also directs research projects and clinical trials in collaboration with scientists at world-class laboratories at Australian and international universities and institutes, including bio-analytical and chemical analyses, in vitro and in vivo studies and clinical trials.
In the past six years, the Company has achieved milestones including proprietary drug discovery, reproducible and practical drug synthesis under GMP conditions, toxicity and safety studies, extensive in vitro, in vivo and human tissue research and Clinical Phase 2 Trial status. With internal expertise, the Company has successfully produced stable and readily bioavailable formulations leveraging the compound.
The company's pipeline includes therapeutics for free radical or inflammatory driven conditions or disease.
We believe a discovery must have the capacity to become a practical reality for people in need. To that end, we drive transformative science that emphasises commercial feasibility with regards to drug manufacture, bioavailability and administration. This practical approach to drug development by RRMS is fundamental to increasing the potential of achieving a successful product endpoint and drug registration while delivering safe human benefit.
Alongside the Company’s internal research activities, RRMS collaborates with world-class scientists at leading Australian and international universities and research institutes. Our collaborators are research specialists in the fields of chemistry and physiology, bio-molecular science, biology, neurology, neuroscience, cardiology, clinical oncology and virology.
Our Scientific Advisors are leaders in their fields and bring independent views to our development based on their extensive careers in areas of medicine and research.
Llewellyn is a research scientist and formulation expert and former MD / CEO of Australian medical companies, including a listed biotech, a veterinary pharmaceutical and a medical device company. His research career began at a multinational centre with Nicholas (Kiwi) Intl and extended to the UK and USA. Llewellyn specialises in the development of metallo-complexes, anti-inflammatory drugs and novel formulation production. He leads development of RRMS’ core discovery and manages research collaborations regarding the novel compound, with findings recently published in Redox Biology.
Llewellyn Casbolt is an Adjunct Fellow, Faculty of Medicine and Health Sciences, Macquarie University, Sydney.
Helena is a new technology development specialist with a deep background in corporate and product communication and marketing, with MD / CEO and founder roles in technology commercialisation start-ups and companies in the USA and Australia. As well, she has both entrepreneurial and successful fundraising experience in the United States and Australia. Helena's experience across various sectors, including public/private health partnerships, medical research and product development, e-commerce, health and personal care products, online financial services, satellite and media technology, and marketing and corporate communications.
Please join our email list for company news and updates.